EGFR exon 20 insertion mutations in non-small cell lung cancer

doi:10.21037/tcr.2020.03.10

	EGFR exon 20 insertion mutations in non-small cell lung cancer
	Wang, Fenfang 2,3; Li, Chenghui 4,5; Wu, Qihuan 1; Lu, Hongyang 5,6
刊名	TRANSLATIONAL CANCER RESEARCH
	2020-04-01
卷号	9
关键词	EGFR exon 20 insertion mutations non-small cell lung cancer (NSCLC) EGFR-TKIs structural features clinical features treatment prognosis
ISSN号	2218-676X
DOI	10.21037/tcr.2020.03.10
通讯作者	Lu, Hongyang(luhy@zjcc.org.cn)
英文摘要	Mutations in the epidermal growth factor receptor (EGFR) gene are the most common targetable genomic drivers of non-small cell lung cancer (NSCLC). 90% of the EGFR mutations comprise of EGFR exon 19 deletion and exon 21 L858R mutation, while EGFR exon 20 insertion (EGFR Ex20Ins) is the third most common type of EGFR mutation. Currently, studies on EGFR Ex20Ins are relatively scarce and limited. The frequency of EGFR Ex20Ins mutations in NSCLC was 1-10%. Patients harboring EGFR Ex20Ins exhibited similar clinical characteristics except for poorer prognosis as compared to patients with sensitizing mutations in EGFR. Conventional TKIs have poor efficacy in a majority of EGFR Ex20Ins subtypes. Chemotherapy remains the preferred treatment for advanced NSCLC patients harboring EGFR Ex20Ins. However, some novel inhibitors are considered as putative candidates. This review focuses on the structural and biochemical features, clinical characteristics, treatments, and prognosis of EGFR Ex20Ins in NSCLC.
资助项目	Zhejiang Province Medical Science Fund[2019ZH019] ; CSCO-Qilu Cancer Research Foundation[Y-Q201802-008] ; 1022 Talent Training Program of Zhejiang Cancer Hospital
WOS关键词	GROWTH-FACTOR-RECEPTOR ; NSCLC PATIENTS ; INHIBITOR ; EFFICACY ; HETEROGENEITY ; OSIMERTINIB ; AFATINIB ; OUTCOMES ; GENE ; RARE
WOS研究方向	Oncology
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000530914200083
资助机构	Zhejiang Province Medical Science Fund ; CSCO-Qilu Cancer Research Foundation ; 1022 Talent Training Program of Zhejiang Cancer Hospital
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/103239]
专题	中国科学院合肥物质科学研究院
通讯作者	Lu, Hongyang
作者单位	1.Xiangshan First Peoples Hosp, Dept Med Emergency, Xiangshan 315700, Peoples R China 2.Xiangshan First Peoples Hosp, Dept Med Oncol, Xiangshan 315700, Peoples R China 3.Wenzhou Med Univ, Grad Sch, Wenzhou 325035, Peoples R China 4.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou 310053, Peoples R China 5.Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Univ Chinese Acad Sci, Dept Thorac Med Oncol,Inst Canc Res & Basic Med S, Hangzhou 310022, Peoples R China 6.Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Univ Chinese Acad Sci,Inst Canc Res & B, Zhejiang Key Lab Diag & Treatment Technol Thorac, Hangzhou 310022, Peoples R China
推荐引用方式 GB/T 7714	Wang, Fenfang,Li, Chenghui,Wu, Qihuan,et al. EGFR exon 20 insertion mutations in non-small cell lung cancer[J]. TRANSLATIONAL CANCER RESEARCH,2020,9.
APA	Wang, Fenfang,Li, Chenghui,Wu, Qihuan,&Lu, Hongyang.(2020).EGFR exon 20 insertion mutations in non-small cell lung cancer.TRANSLATIONAL CANCER RESEARCH,9.
MLA	Wang, Fenfang,et al."EGFR exon 20 insertion mutations in non-small cell lung cancer".TRANSLATIONAL CANCER RESEARCH 9(2020).